重组人血管内皮抑制素联合三维适形放疗治疗局部晚期非小细胞肺癌的临床疗效  

Clinical effect of recombinant human endostatin combined with three dimensional conformal radiotherapy on treatment of local advanced non-small cell lung cancer

作　　者：刘荣强[1] 张淑芳[1] 

机构地区：[1]福建医科大学附属南平市第一医院放疗科,福建南平350005

出　　处：《实用临床医药杂志》2014年第16期75-77,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金项目(11321588)

摘　　要：目的探讨重组人血管内皮抑制素联合三维适形放疗治疗局部晚期非小细胞肺癌（NSCLC）的疗效。方法选取经病理组织学或细胞学检查确诊的ⅢA-ⅢB期NSCLC患者78例,分为对照组和试验组,每组39例。对照组采用单纯三维适形放疗,试验组采用重组人血管内皮抑制素联合三维适形放疗。治疗2周期评价疗效及不良反应,至随访结束观察生存期。结果试验组的客观缓解率（RR）为69.2%,疾病控制率（DCR）为89.7%;对照组RR为33.3%,DCR为71.8%。试验组的RR、DCR显著高于对照组（P〈0.05或P〈0.01）。2组不良反应以贫血、恶心呕吐、白细胞减少、放射性肺损伤为主,均可耐受。至截止时间,试验组中位无进展生存期为8个月,中位生存期为13个月,对照组中位无进展生存期为5个月,中位生存期为9个月。结论重组人血管内皮抑制素联合三维适形放疗治疗晚期NSCLC的疗效优于单纯三维适形放疗,不良反应无明显增加。Objective To explore the clinical efficacy of recombinant human endostatin（endostar） combined with three dimensional conformal radiotherapy（3D-CRT） on treatment of patients with non-small cell lung cancer（NSCLC）. Methods 78 patients with NSCLC in phase ⅢA ~ ⅢB by histopathology and cytology were randomly divided into control group（treated with single 3D-CRT）and experiment group（treated with endostar and 3D-CRT）,39 cases in each group. Clinical efficacy and adverse responses were evaluated after two cycles of treatment and survival time was observed until the end of follow-up. Results The objective remission rate（RR） and disease control rate（DCR） in experiment group were 69. 2% and 89. 7% respectively,which were evidently higher than the 33. 3%and 71. 8% in control group（P 0. 05 or P 0. 01）. The main adverse responses in both groups were anemia,nausea and vomiting,leukopenia and radioactive lung injury and all were tolerable. Until the end of follow-up,the medium progression free survival time and medium survival time in experimental group were 8 and 13 months,and in control group were 5 and 9 months respectively. Conclusion Endostar combined with 3D-CRT are superior to single 3D-CRT without increasing adverse responses in the treatment of NSCLC.

关 键 词：重组人血管内皮抑制素 三维适形放疗 非小细胞肺癌 生存期 放射性肺损伤 

分 类 号：R734.2[医药卫生—肿瘤]